FDA Approves, CMS Proposes Coverage of First Test to Detect Extensive Number of Cancer Biomarkers
The U.S. Food and Drug Administration approved the FoundationOne CDx, the first breakthrough-designated, next generation sequencing (NGS)-based in vitro diagnostic test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.